Filter Results:
(624)
Show Results For
- All HBS Web
(624)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
Show Results For
- All HBS Web
(624)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (C)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (C)." Harvard Business School Case 603-045, June 2003. (Revised October 2004.)
- March 2002 (Revised May 2002)
- Case
Genzyme: Engineering the Market for Orphan Drugs
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Biotechnology Industry; Biotechnology Industry
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
- September 2001
- Supplement
Millennium Pharmaceuticals, Inc. (B)
By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 602-063, September 2001.
- October 2000
- Teaching Note
Kendle International Inc. TN
By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details
- September 1997
- Case
Bayer AG (B)
By: John A. Quelch
Bayer's senior executives detail the communications challenge program that resulted from the company's reacquisition of its brand name and trademark cross, which gave Bayer one name worldwide for the first time since World War I. View Details
Keywords: Globalized Firms and Management; War; Acquisition; Trademarks; Brands and Branding; Communication Strategy; Biotechnology Industry; Biotechnology Industry; Germany
Quelch, John A., and Robin Root. "Bayer AG (B)." Harvard Business School Case 598-032, September 1997.
- 2000
- Chapter
In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals
By: Gary P. Pisano
Keywords: Competency and Skills; Research and Development; Biotechnology Industry; Biotechnology Industry
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
- September 2008 (Revised July 2012)
- Case
Khosla Ventures: Biofuels Strategy
By: Joseph B. Lassiter III, William A. Sahlman and Alison Berkley Wagonfeld
By 2008, a number of the firm's early cleantech investments were showing promise, and the companies were starting to need significantly more money to create the massive scale required in the energy sector. As Khosla thought about the hundreds of millions of dollars... View Details
Keywords: Entrepreneurial Marketing; Entrepreneurial Finance; New Product Development; Partnerships; Entrepreneurial Management; Venture Capital; Strategy; Partners and Partnerships; Renewable Energy; Entrepreneurship; Investment Funds; Environmental Sustainability; Product Development; Biotechnology Industry; Biotechnology Industry
Lassiter, Joseph B., III, William A. Sahlman, and Alison Berkley Wagonfeld. "Khosla Ventures: Biofuels Strategy." Harvard Business School Case 809-004, September 2008. (Revised July 2012.)
- 12 Mar 2013
- First Look
First Look: March 12
A. Arnaout Publication:Nature Biotechnology Abstract Advances in biotechnology have fueled the generation of unprecedented quantities of data across the life sciences. However, finding analysts who can... View Details
Keywords: Sean Silverthorne
- 01 Nov 2024
- In Practice
Layoffs Surging in a Strong Economy? Advice for Navigating Uncertain Times
decision about entrepreneurship Starting your own company after a layoff is a significant decision. While it may seem like an opportune time, research suggests there are some important considerations. “Entrepreneurs coming from high-tech sectors such as View Details
- 14 Jul 2009
- First Look
First Look: July 14
biotechnology deals. Purchase this case: http://hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=309112 Goldman Sachs: The 10,000 Women Initiative Harvard Business School Case 509-042 Describes the conception, development, and... View Details
Keywords: Martha Lagace
- 20 Sep 2021
- Blog Post
Student Spotlight: Summer Internships in Business and Environment
fermentation in a carbon-negative biotechnology process. Solugen envisions a global-scale network of automated, carbon-sequestering mini-mills that are multi-product, drastically impacting the way chemicals are produced and transported... View Details
- 17 Oct 2006
- First Look
First Look: October 17, 2006
started her own hedge fund firm in 2001 after nearly 20 years as a star biotechnology analyst and hedge fund manager. After the start-up phase, her firm became highly profitable. In 2004, however, one of her four analysts lost a lot of... View Details
Keywords: Sean Silverthorne
- 22 Nov 2016
- First Look
November 22, 2016
commercial implications—the technology would be immensely important to biotechnology firms looking to develop gene therapy products and was, therefore, sure to generate strong revenues for whichever entity owned the IP—but would also... View Details
Keywords: Sean Silverthorne
- Profile
Terrance McGuire
and entrepreneur, during which time they have collaborated on a long list of successful biotechnology startups. “Bob Langer is passionate about improving peoples' lives,” McGuire said. “He was one of the early... View Details
- 03 Dec 2001
- Research & Ideas
Healthcare Conference Looks At Ailing Industry
Mixing Risk And Reward The basic model that the biotechnology industry has followed for over twenty years is also changing, and for the better, according to panelists at a session titled "Will Equal Biotechnology-Pharma Partnerships... View Details
- 15 Feb 2022
- Blog Post
Health is Wealth | The Path to Creating a Venture
her sleep patterns – to try to improve her performance. It was during this time that she connected with Wallerstofer, who had a PhD in biotechnology and had spent the previous decade building consumer facing nutrition products based on... View Details
- 06 Oct 2020
- Blog Post
2+2 Where Are They Now Spotlight: Curtis Wu (MBA 2018)
Can you describe your role?I currently work at Amgen Inc at their global HQ in Southern California. Amgen is the largest independent biotechnology company in the world by revenue and our top medicines include autoimmune drug Enbrel, white... View Details
- 01 Aug 2002
- News
For Alumni Only: Breakthrough Insights Program Debuts
case on the biotechnology firm Biogen, where a seemingly innocuous decision to license databases of new proteins discovered through genomic research wound up completely transforming the company's product-development process. As Vietor led... View Details
Keywords: Laura Singleton
- 11 May 2010
- First Look
First Look: May 11
Amyris Biotechnologies: Commercializing Biofuel Gary P. Pisano and Alison Berkley WagonfeldHarvard Business School Case 610-031 In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic biology to convert... View Details
Keywords: Martha Lagace
- Research Summary
Evolution of firm structure in vertical specialized technology supply chains
By: Willy C. Shih
The global market in many everyday products has been transformed by the internationalization of production. In many industries, semiconductors and electronic products in particular, a sequential mode of production has evolved in which goods are produced... View Details